r.classen / Shutterstock.com

4 August 2025NewsEuropeMarisa Woutersen

Pfizer loses UK appeal over Moderna Covid-19 vaccine patent

UK Court of Appeal upholds key Moderna patent against Pfizer and BioNTech | Comirnaty vaccine ruled to infringe European mRNA technology patent.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pfizer, Moderna vow appeals after split vaccine ruling

4 July 2024 UK leg of global litigation over mRNA tech sees patents ruled valid and invalid | Justice Meade follows EPO in decision on Moderna’s EP 565 patent | Pfizer and German partner BioNTech on the hook for EP 949 | Opinion on Moderna’s COVID pledge also handed down.

Biotechnology

Moderna prevails in COVID-19 vaccine row at EPO

21 May 2024 Despite attempts by Pfizer and BioNTech to invalidate the patent, the ruling strengthens Moderna’s position in ongoing global litigation | Pfizer is considering an appeal, while BioNTech remains steadfast in defending its innovations.

Moderna’s COVID-19 pledge dilemma

16 May 2024 As the company challenges Pfizer and BioNTech over COVID-19 vaccine patents, issues over the enforceability of pledges made during the pandemic may make pharma think twice in future, finds Marisa Woutersen.

More on this story

Pfizer, Moderna vow appeals after split vaccine ruling

4 July 2024 UK leg of global litigation over mRNA tech sees patents ruled valid and invalid | Justice Meade follows EPO in decision on Moderna’s EP 565 patent | Pfizer and German partner BioNTech on the hook for EP 949 | Opinion on Moderna’s COVID pledge also handed down.

Biotechnology

Moderna prevails in COVID-19 vaccine row at EPO

21 May 2024 Despite attempts by Pfizer and BioNTech to invalidate the patent, the ruling strengthens Moderna’s position in ongoing global litigation | Pfizer is considering an appeal, while BioNTech remains steadfast in defending its innovations.

Moderna’s COVID-19 pledge dilemma

16 May 2024 As the company challenges Pfizer and BioNTech over COVID-19 vaccine patents, issues over the enforceability of pledges made during the pandemic may make pharma think twice in future, finds Marisa Woutersen.

More on this story

Pfizer, Moderna vow appeals after split vaccine ruling

4 July 2024 UK leg of global litigation over mRNA tech sees patents ruled valid and invalid | Justice Meade follows EPO in decision on Moderna’s EP 565 patent | Pfizer and German partner BioNTech on the hook for EP 949 | Opinion on Moderna’s COVID pledge also handed down.

Biotechnology

Moderna prevails in COVID-19 vaccine row at EPO

21 May 2024 Despite attempts by Pfizer and BioNTech to invalidate the patent, the ruling strengthens Moderna’s position in ongoing global litigation | Pfizer is considering an appeal, while BioNTech remains steadfast in defending its innovations.

Moderna’s COVID-19 pledge dilemma

16 May 2024 As the company challenges Pfizer and BioNTech over COVID-19 vaccine patents, issues over the enforceability of pledges made during the pandemic may make pharma think twice in future, finds Marisa Woutersen.

More features

Bayer’s Xarelto patent struck down by German court

Teva draws line under asthma inhaler feud with US rival

Xanax owner fends off ‘Canvax’ mark in EU

Four-lawyer team joins Cozen O’Connor’s new San Diego office

WATCH: Beyond patents — the evolving role of IP lawyers in life sciences

Could Apple v Masimo limit patent cases at the ITC?

Eli Lilly strikes again in weight-loss drugs fight

Novartis moves to block cancer drug generic in US